Pittenger & Anderson Inc. grew its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 4.5% during the second quarter, Holdings Channel.com reports. The fund owned 8,396 shares of the medical instruments supplier’s stock after purchasing an additional 365 shares during the quarter. Pittenger & Anderson Inc.’s holdings in West Pharmaceutical Services were worth $2,539,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in WST. Allworth Financial LP boosted its stake in shares of West Pharmaceutical Services by 140.0% during the first quarter. Allworth Financial LP now owns 72 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 42 shares in the last quarter. Addison Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 221.7% during the first quarter. Addison Advisors LLC now owns 74 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 51 shares in the last quarter. Artemis Wealth Advisors LLC bought a new position in shares of West Pharmaceutical Services during the first quarter valued at approximately $35,000. American National Bank boosted its stake in shares of West Pharmaceutical Services by 55.6% during the first quarter. American National Bank now owns 98 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 35 shares in the last quarter. Finally, Dividend Assets Capital LLC bought a new position in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $51,000. 91.98% of the stock is currently owned by institutional investors.
Insider Activity at West Pharmaceutical Services
In related news, insider Silji Abraham sold 5,374 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the completion of the sale, the insider now owns 3,201 shares of the company’s stock, valued at $1,100,919.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.60% of the stock is currently owned by corporate insiders.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services (NYSE:WST – Get Rating) last posted its earnings results on Thursday, July 28th. The medical instruments supplier reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.28. West Pharmaceutical Services had a net margin of 23.41% and a return on equity of 29.08%. The company had revenue of $771.30 million during the quarter, compared to analysts’ expectations of $754.25 million. During the same quarter in the prior year, the company posted $2.46 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 6.6% compared to the same quarter last year. Sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 9.09 EPS for the current fiscal year.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.